Result: There were no drug resistant mutations (lamivudine-resistant pattern: rtM204V/I, rtL180M, rtV173L, adefovir-resistant pattern: rtA181V/T, tenofovir-resistant pattern: rtA194T and entecavir-resistant pattern: rtL180M, rtS202G, rtM204V) detectable in acute patients belonging to our study population.
[Variability of Reverse Transcriptase Gene and S Gene in Lamivudine-treated Chronic Hepatitis B Patients].
Abstract: rtL180M coexisted with rtM204V (5/5, 100%).
Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
PMID: 26386408
2015
Transactions of the Royal Society of Tropical Medicine and Hygiene
Abstract: Of the 23 patients in whom HBV-DNA sequencing was successful, 17 had lamivudine-resistant HBV strains harbouring rtM204V/I mutations accompanied by secondary/compensatory mutations.
Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment.
PMID: 26382925
2015
The Journal of general virology
Abstract: Furthermore, double mutations rtL80I/M204I and rtL80V/M204V had replication efficiency similar to that of rtL80I and rtL80V, respectively.
Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Abstract: In this regard, homology modeled structure of HBV polymerase was used for minimization, conformational search and Glide XP docking followed by binding energy calculation on wild-type as well as on mutant HBV-polymerases (N236T, L180M+M204V+S202G & A194T).
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
Introduction: The primary mutation conferring LMV resistance is
Table: M204V
Discussion: rtM204I/V in the YMDD motif is the primary mutation conferring resistance against LMV, CLV, and ETV.
Discussion: However, among the 16 patients in whom the YMDD mutation was detectable during antiviral treatment, 7 (43.8%) displayed the rtL269I substitution along with rtM204I/V mutation (Table 1).
Discussion: These clinical data suggested that rtM204I/V+L269I was selected during antiviral therapy to confer viral fitness.
Detection and analysis of resistance mutations of hepatitis B virus.
PMID: 26309637
2015
International journal of clinical and experimental medicine
Abstract: L180M, M204I and M204V were associated with the resistance to lamivudine and telbivudine; L180M, M204I, M204V and V173L were associated with the resistance to entecavir; A181T, N236T and N/H238T were related to the resistance to adefovir.
Abstract: Of multi-base mutations, L180M combined M204V had a high prevalence and were frequently found in patients with resistance to lamivudine and telbivudine.
Abstract: Of single base mutation, L180M, M204I, M
YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy.
Discussion: The results of mutations were similar to those of the previous studies reporting that the most common mutation affects the highly conserved YMDD motif, resulting in a methionine to valine or isoleucine substitution at codon 204 (M204V/I) and between them, M204I mutant is significantly more resistant to LAM than the M204V mutant.
Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro.
PMID: 26220282
2015
BMC complementary and alternative medicine
Abstract: METHODS: HBV harboring LMV-resistant mutations (rtM204I, rtM204V, and rtM204S) in the P gene at the YMDD ((203)tyrosine-methionine-aspartate-aspartate(206)) reverse transcriptase (RT) active site were generated and their sensitivity to Phyllanthus urinaria koreanis extract examined.
Method: The YMDD (203tyrosine-methionine-aspartate-aspartate206)
Result: M204V or M204I are the most frequently observed mutations in this region, and confer resistance to LMV, LdT, and ETV.
Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone.
Abstract: Seven patients had evidence of virological rebound, of whom 6 had evidence of rtM204V/I mutation and 1 had recurrence of hepatocellular carcinoma with low-level rebound and wild-type virus.
HBV mutation literature information.
PMID: 
2015
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT